Piramal Pharma
CDMO and hospital generics, consumer health
Manager Packaging Technology
About the job
- A bachelor's degree in Mechanical Engineering or graduation in Packaging Technology.
- Eight to fourteen years of professional experience in the pharmaceutical or medical device industry; sterile product experience is preferred.
- Experience developing primary container designs and specifications and supporting primary packaging regulatory filings.
- Project management experience with a proven track record in packaging or engineering.
- Experience writing technical documentation for regulatory files, including FDA 510(k) and CE mark technical files.
- Strong understanding of global packaging and medical device regulations.
- Experience in sterile packaging development and exposure to medical device development.
- Experience developing primary packaging components, including stability studies, machine feasibility studies, packaging trials, regulatory filings, shipping studies, and validation.
- Knowledge of ASTM and ISO standards and experience preparing testing procedures and interpreting test data.
- Experience with design control and quality management system procedures.
- Experience with root cause analysis and corrective and preventive actions.
- Experience with distribution testing, shipping studies, line trials, packaging material qualifications, child-resistant requirements, human factor studies, and patient-centric designs.
- Develop, test, validate, and commercialize packaging solutions and medical devices for new and existing products.
- Support continuous improvements, problem resolution, and redesign for marketed products.
- Support new product development, technical documentation for regulatory files, performance analysis, risk management, and design transfer to manufacturing.
- Design packaging systems for anesthetic and sterile drug products, including ampoules, vials, and prefilled syringes, with primary, secondary, and tertiary packaging components and packaging-process automation equipment.
- Handle contract manufacturing organization sites for the injectable vertical and provide complete documentation support, including eMPD and eSPEC.
- Develop three-dimensional computer-aided design and SolidWorks models of parts and assemblies and create engineering drawings for products, components, and tooling.
- Coordinate with manufacturing, supply chain management, and logistics teams to understand challenges and improvement opportunities.
- Use three-dimensional printing and additive manufacturing for prototyping and low-volume production.
- Select components and materials for product design and development.
- Prepare protocols and testing procedures according to ASTM and ISO standards and analyze and interpret test data.
- Prepare technical documentation for FDA 510(k) and CE mark regulatory files.
- Create, improve, and maintain design control and quality management system procedures with Quality and Regulatory teams.
- Perform root cause analysis, provide recommendations, write and implement corrective and preventive actions, verify effectiveness, and provide required training.
- Create product-priority timelines and coordinate with team members.
- Develop, review, and approve packaging component specifications, packaging component drawings, design history files for combination products, project value-stream mapping, and procedures for bulk and finished drug products.
- Support primary packaging regulatory filings.
- Identify and validate secondary and tertiary packaging materials and suppliers.
- Execute harmonization, standardization, quality-risk remediation or reduction, and continuous-improvement projects.
- Develop, track, and maintain project plans and budgets for packaging-related projects.
- Originate and develop packaging projects and initiatives that improve processes and create significant business impact.
- Support sustainability and green-packaging initiatives.
- Experience in sterile product development.
About the company
Piramal Pharma operates through three divisions: Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and the Consumer Products Division (CPD). PPS acts as a contract development and manufacturing organization (CDMO), offering development and manufacturing services across the drug lifecycle for clients in North America, Europe, and Asia. PCC specializes in complex hospital generics, especially inhaled anesthetics, serving the USA, Europe, and more than 100 countries. CPD markets consumer health brands in India, including Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri Activ, and aims to provide reliable development, manufacturing, and distribution capabilities to meet customer needs.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
India
Founded
2020
Get referred to Piramal Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- Yapan Bio became a subsidiary on August 18, 2026, strengthening biologics and vaccines.
- Kenalog supply starts in Q2FY27, adding $30-40 million annualized revenue.
- Morpeth solar begins Q1 2027, cutting Scope 1 and 2 emissions 42% by FY2030.
What critics are saying
- FDA issued a Form 483 with seven observations at Morpeth on September 14, 2026.
- Q1 FY27 revenue fell 17.5%; inventory destocking and weak early-stage CDMO inflows persist.
- If Morpeth remediation slips, UK supply, customer trust, and CDMO wins stall into 2027.
What makes Piramal Pharma unique
- Piramal spans CDMO, hospital generics, and Indian consumer healthcare across 100+ countries.
- PPS offers ADCs, sterile fill-finish, peptides, and biologics through Yapan Bio.
- Kenalog and inhaled anesthetics give Piramal harder-to-replicate niche products and hospital channels.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Stock Options
Growth & Insights and Company News
6 month growth
↓ -6%1 year growth
↓ -6%2 year growth
↓ -1%Piramal Pharma Solutions advances sustainability efforts with solar power plant addition at Morpeth, UK site. Sep 16, 2026, 10:14 ET * Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. * The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal's commitment to reduce Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030. MUMBAI, India, Sept. 16, 2026 /CNW/ - Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), is strengthening its decarbonization efforts with the addition of a 4.3 MWp ground-mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, UK. Once operational, the plant will supply the site with approximately 3,950 MWh of renewable electricity each year, meeting around 22% of its annual electricity demand. Featuring around 6,200 solar panels across 16 acres of land, the installation will produce enough clean energy to power approximately 1,460 UK homes per year. The project is being delivered under a Power Purchase Agreement (PPA) with Alight UK BTM1 Limited ("Alight"), a leading solar developer and independent power producer. This initiative will enable Morpeth to avoid an estimated 20,000 tCO[2]e over 25 years, marking a significant step forward in PPL's sustainability journey and long-term decarbonization strategy. By implementing a sustainable, cost-effective solution for onsite electricity generation, PPL is enhancing the resilience of its energy supply while demonstrating its commitment to a lower-carbon future. "At Piramal Pharma Solutions, we integrate sustainability principles into every operation and decision across our global network," said Frank Bugg, Senior Vice President, UK & Europe Operations and Managing Director, Piramal Pharma Solutions. "We are excited to advance our commitment to decarbonization and renewable energy with our partner Alight, bringing new value to our customers and shareholders worldwide." "Businesses across the UK are looking for practical ways to lower emissions, strengthen energy resilience, and manage long-term energy costs. This project with Piramal Pharma shows how onsite solar can deliver all three," says Rob Stait, Managing Director, Behind the Meter at Alight. Project operations are scheduled to begin in the first quarter of 2027. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. SOURCE Piramal Pharma Solutions For Investor Queries: Gagan Borana | Investor Relations & Enterprise Risk Management | [email protected], For Media Queries: Madiha Vahid | Lead - Branding & Communications | [email protected]
Piramal Pharma Limited completes acquisition of controlling stake in Yapan Bio Private Limited. Aug 18, 2026, 15:36 ET * Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing. * This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services. MUMBAI, India, Aug. 18, 2026 /PRNewswire/ - Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL. Finalized on August 18, 2026, the acquisition marks a major step forward in PPL's long-range plan to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary's advanced large molecule capabilities into its integrated service offering, enabling the Company to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate(TM)- PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate(TM) and reinforces PPL's ability to deliver life-saving ADCs to market with speed and consistency. "This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action," said Peter DeYoung, CEO, Piramal Global Pharma. "By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need." About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. SOURCE Piramal Pharma Solutions
Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio for ₹76 crore, increasing its shareholding from 33.33% to 74%. The Mumbai-based pharmaceutical company purchased 146,400 equity shares, converting Yapan Bio from an associate company to a subsidiary. Yapan Bio, founded in 2019, is a Contract Development and Manufacturing Organisation specialising in vaccines and biologics. The company reported revenues of ₹26.91 crore, ₹54.40 crore, and ₹26.34 crore for fiscal years 2024, 2025, and 2026 respectively. The acquisition strengthens Piramal Pharma's biologics capabilities and expands its integrated service offerings. The company announced its intention to exercise this call option in August 2026, completing the transaction as disclosed in a regulatory filing to the National Stock Exchange.
Piramal Pharma Ltd invested INR 101.77 crore in Hyderabad-based Yapan Bio Pvt Ltd in December 2021, acquiring a 27.78% equity stake. The investment aimed to strengthen Piramal Pharma Solutions' CDMO capabilities in biologics and vaccines, particularly for large molecule development and manufacturing for human clinical trials. In April 2022, Piramal increased its stake by 5.55% for Rs 20.35 crore, bringing total ownership to 33.33% by March 2023. The company's FY2023 filings showed Yapan's share of loss at Rs 0.20 crore. In October 2022, Yapan expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, as part of a $1 million expansion plan. The facility supports end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. Yapan's services are marketed through Piramal Pharma Solutions.
Piramal Pharma expects to accelerate earnings growth over the next two to three years, driven by rising demand for complex drugs including targeted cancer therapies, chairperson Nandini Piramal said. The Indian drugmaker, which derives 55% of revenue from contract manufacturing, aims for early-to-mid-teens revenue growth after reporting a 3% drop in fiscal 2026. The company is prioritising higher-value segments, particularly antibody-drug conjugates for cancer treatment, as global biotech funding into Indian contract manufacturers rebounds. Biotech funding in the second half of 2024 was 80% higher year-on-year, translating into increased order inflows. Piramal is avoiding generic weight-loss drug ingredients due to intense competition and falling prices. The company's contract manufacturing revenue fell 10% last year, causing margins to shrink from 17% to 13%.